Having excess levels of PCSK9 is not sufficient to induce complex formation between PCSK9 and the LDL receptor

被引:10
作者
Wooten, Catherine J. [1 ]
Adcock, Audrey F. [1 ]
Agina-Obu, DaTonye I. [1 ]
Lopez, Dayami [1 ]
机构
[1] N Carolina Cent Univ, Coll Arts & Sci, BR1TE, Dept Pharmaceut Sci, Durham, NC 27707 USA
关键词
LDL receptor; LDL; PCSK9; IDOL; Human hepatocyte-like C3A cells; DENSITY-LIPOPROTEIN RECEPTOR; CONVERTASE SUBTILISIN/KEXIN TYPE-9; HEPATOCELLULAR-CARCINOMA; CHOLESTEROL REDUCTION; MONOCLONAL-ANTIBODY; SQUALENE SYNTHASE; ANNEXIN A2; DEGRADATION; INHIBITION; STATINS;
D O I
10.1016/j.abb.2014.01.018
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Proprotein convertase subtilisin/kexin-9 (PCSK9) acts mainly by forming complexes with the LDL receptor at the cell surface, which are then degraded in the lysosome. Studies were performed to determine whether excess levels of PCSK9 was sufficient to induce PCSK9/LDL receptor complex formation in human hepatocyte-like C3A cells. It was demonstrated using ELISA that instead of considering the overall levels of PCSK9 protein that is produced in response to certain treatment, what is critical is how much PCSK9 is actually capable of forming complexes. Despite the high levels, most of the PCSK9 produced as a result of incubating cells with a medium supplemented with BD (TM) MITO+ serum extender (MITO+ medium) appeared to be inhibited by a secreted factor. Having lower levels of PCSK9/LDL receptor complexes did not prevent an increase in the degradation rate of LDL receptors in MITO+ medium as compared to fetal bovine serum (FBS) containing medium (Regular medium), an effect that did not correlate with an increase in protein levels of the inducible degrader of LDL receptors (IDOL), as demonstrated using Western blotting analysis. Additional studies are required to determine the exact mechanism(s) for the degradation of the LDL receptor and/or to identify the secreted inhibitor of PCSK9. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码:124 / 132
页数:9
相关论文
共 37 条
[1]   MONENSIN INTERRUPTS THE RECYCLING OF LOW-DENSITY LIPOPROTEIN RECEPTORS IN HUMAN-FIBROBLASTS [J].
BASU, SK ;
GOLDSTEIN, JL ;
ANDERSON, RGW ;
BROWN, MS .
CELL, 1981, 24 (02) :493-502
[2]   Inhibition of squalene synthase upregulates PCSK9 expression in rat liver [J].
Bedi, Mohini ;
Niesen, Melissa ;
Lopez, Dayami .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2008, 470 (02) :116-119
[3]   FERM-dependent E3 ligase recognition is a conserved mechanism for targeted degradation of lipoprotein receptors [J].
Calkin, Anna C. ;
Goult, Benjamin T. ;
Zhang, Li ;
Fairall, Louise ;
Hong, Cynthia ;
Schwabe, John W. R. ;
Tontonoz, Peter .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (50) :20107-20112
[4]   Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9 [J].
Careskey, Holly E. ;
Davis, R. Aleks ;
Alborn, William E. ;
Troutt, Jason S. ;
Cao, Guoqing ;
Konrad, Robert J. .
JOURNAL OF LIPID RESEARCH, 2008, 49 (02) :394-398
[5]   Genetic Determinants of Statin-Induced Low-Density Lipoprotein Cholesterol Reduction The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial [J].
Chasman, Daniel I. ;
Giulianini, Franco ;
MacFadyen, Jean ;
Barratt, Bryan J. ;
Nyberg, Fredrik ;
Ridker, Paul M. .
CIRCULATION-CARDIOVASCULAR GENETICS, 2012, 5 (02) :257-264
[6]   Current, new and future treatments in dyslipidaemia and atherosclerosis [J].
Chong, PH ;
Bachenheimer, BS .
DRUGS, 2000, 60 (01) :55-93
[7]   The Influence of PCSK9 Polymorphisms on Serum Low-Density Lipoprotein Cholesterol and Risk of Atherosclerosis [J].
Davignon, Jean ;
Dubuc, Genevieve ;
Seidah, Nabil G. .
CURRENT ATHEROSCLEROSIS REPORTS, 2010, 12 (05) :308-315
[8]   The E3 Ubiquitin Ligase SMAD Ubiquitination Regulatory Factor 2 Negatively Regulates Kruppel-like Factor 5 Protein [J].
Du, James X. ;
Hagos, Engda G. ;
Nandan, Mandayam O. ;
Bialkowska, Agnieszka B. ;
Yu, Bing ;
Yang, Vincent W. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (46) :40354-40364
[9]  
ESKO JD, 1983, J BIOL CHEM, V258, P3051
[10]   In Vivo Evidence That Furin from Hepatocytes Inactivates PCSK9 [J].
Essalmani, Rachid ;
Susan-Resiga, Delia ;
Chamberland, Ann ;
Abifadel, Marianne ;
Creemers, John W. ;
Boileau, Catherine ;
Seidah, Nabil G. ;
Prat, Annik .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (06) :4257-4263